Kawachi Pharmaceuticals achieved sales of 71.9 billion yen (YoY +1.3%), operating profit of 1.447 billion yen (+15.9%), and net income attributable to owners of the parent of 1.12 billion yen (+5.5%) in the first quarter of the fiscal year ending March 2027. Although the number of stores decreased to 385, profitability was maintained through cost review and sales promotion initiatives.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"2664","jir_company_name":"Kawachi Pharmaceuticals Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-07-29","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/07\/2664-20260729-01.pdf","jir_short_summary":"Kawachi Pharmaceuticals achieved sales of 71.9 billion yen (YoY +1.3%), operating profit of 1.447 billion yen (+15.9%), and net income attributable to owners of the parent of 1.12 billion yen (+5.5%) in the first quarter of the fiscal year ending March 2027. Although the number of stores decreased to 385, profitability was maintained through cost review and sales promotion initiatives.","jir_summary":"### Overview of Business Performance\nKawachi Pharmaceuticals recorded net sales of 71.981 billion yen (YoY +1.3%), operating profit of 1.447 billion yen (+15.9%), ordinary income of 1.710 billion yen (+6.2%), and net income attributable to owners of the parent of 1.12 billion yen (+5.5%) in the first quarter of the fiscal year ending March 2027. The increase in sales was driven by effects of cost review and sales promotion measures. Despite reducing the number of stores to 385, profitability improved with higher sales and earnings, demonstrating a steady performance trend.\n\n### Financial Position and Future Outlook\nTotal assets decreased slightly from 20.255 billion yen to 20.254 billion yen. However, current assets increased due to higher cash and deposits. Liabilities increased mainly due to an increase in accounts payable, while net assets declined due to dividend payments. The equity ratio slightly decreased to 56.7%. Going forward, the company will continue to focus on cost management and sales promotion to ensure stable earnings.","jir_financial_highlights":"Net sales: 71.981 billion yen (YoY +1.3%)\nOperating profit: 1.447 billion yen (YoY +15.9%)\nQuarterly net income attributable to owners of the parent: 1.12 billion yen (YoY +5.5%)","jir_category":"","jir_hashtags":"#KawachiPharmaceuticals, #IRFinancialResults, #JapanStocks","jir_key_figures":"Net sales: 71.981 billion yen (YoY +1.3%)\nOperating profit: 1.447 billion yen (YoY +15.9%)\nNet income attributable to owners of the parent: 1.12 billion yen (YoY +5.5%)","jir_meta_title":"\u3010Kawachi Pharmaceuticals\u3011Q1 2027 Earnings\uff5cSales 71.9 billion yen (+1.3%)","jir_meta_description":"Kawachi Pharmaceuticals achieved sales of 71.9 billion yen, operating profit of 1.4 billion yen, and net income of 1.1 billion yen in Q1 2027. Cost review and sales promotion contributed to increased earnings.","jir_og_title":"\u3010Kawachi Pharmaceuticals\u3011Q1 2027 Earnings\uff5cSales 71.9 billion yen (+1.3%)","jir_og_description":"The Q1 2027 financial results of Kawachi Pharmaceuticals show sales of 71.9 billion yen, operating profit of 1.4 billion yen, and net income of 1.1 billion yen. Cost efficiency and sales promotion efforts were effective.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":16960,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-89511","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n